Genomics

Dataset Information

0

Cell context is the third axis of synergy for ATR inhibition and cisplatin in Ewing sarcoma


ABSTRACT: Purpose: The importance of cellular context to the synergy of DNA Damage Response (DDR) targeted agents is important for tumors with mutations in DDR pathways, but less well-established for tumors driven by oncogenic transcription factors. In this study, we exploit the widespread transcriptional dysregulation of the EWS-FLI1 transcription factor to identify an effective DDR targeted combination therapy for Ewing Sarcoma (ES). Experimental Design: We used matrix drug screening to evaluate synergy between a DNA-PK inhibitor (M9831) or an ATR inhibitor (berzosertib) and chemotherapy. The combination of berzosertib and cisplatin was selected for broad synergy, mechanistically evaluated for ES selectivity, and optimized for in vivo schedule. Results: Berzosertib combined with cisplatin demonstrates profound synergy in multiple ES cell lines at clinically achievable concentrations. The synergy is due to loss of expression of the ATR downstream target CHEK1, loss of cell cycle checkpoints, and mitotic catastrophe. Consistent with the goals of the project, EWS-FLI1 drives the expression of CHEK1 and five other ATR pathway members. The loss of expression is not due to transcriptional repression and instead caused by degradation coupled with suppression of protein translation. The profound synergy is realized in vivo with a novel optimized schedule of this combination in subsets of ES models leading to durable complete responses in 50% of animals bearing two different ES xenografts. Conclusions: These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule.

ORGANISM(S): Homo sapiens

PROVIDER: GSE260602 | GEO | 2024/03/13

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2017-09-14 | GSE103837 | GEO
2015-03-31 | E-GEOD-65941 | biostudies-arrayexpress
2015-03-31 | GSE65941 | GEO
2017-07-06 | GSE92737 | GEO
2017-07-06 | GSE92739 | GEO
2017-07-06 | GSE92738 | GEO
2024-11-04 | GSE229906 | GEO
2019-08-30 | GSE115676 | GEO
2024-01-26 | PXD041033 | Pride
2022-05-12 | PXD027309 | Pride